Compare AbbVie Inc (ABBV) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Citius Pharmaceuticals Inc — how do they compare? AbbVie Inc trades at $248.7 (market cap $441.94B), while Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M). The key difference: AbbVie Inc is far larger — about 22086× Citius Pharmaceuticals Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ABBV | CTXR | |
|---|---|---|
Market Cap | $441.94B | $20.01M |
Sector | Health | Health |
52-Week High | $263.58 | $1.82 |
52-Week Low | $197.38 | $0.48 |
Enterprise Value | $506.19B | $16.23M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $248.40, up 0.2% with a bullish technical signal supported by moving averages. The company demonstrates strong revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional buying activity highlight ongoing momentum. Valuation ratios appear elevated with a P/E of 70.65 and P/B of 245.29, reflecting premium pricing for its pharmaceutical pipeline.
Outlook remains positive with 70.7% analyst buy ratings and a $278.69 consensus target offering 12% upside. Key risks include patent expirations, regulatory challenges from drug pricing lawsuits, and high debt levels. The dividend aristocrat status and robust immunology portfolio position ABBV for sustained growth, though investors should monitor execution against lofty 2026 EPS expectations of $3.87 for Q3.
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
